Menu
Oslo, Norway, 1 August 2025: Reference is made to stock exchange announcements by Thor Medical ASA (the "Company") on 18 June 2025 regarding the completion of the subsequent offering of a total of 4,000,000 new shares in the Company raising a total of NOK 10 million in gross proceeds (the "Subsequent Offering").
The share capital increase relating the Subsequent Offering is now registered with the Norwegian Register of Business Enterprises. The Company's share capital is after the registration NOK 70,597,184 divided into 352,985,920 shares. Each share has a nominal value of NOK 0.20 and represents one vote in the Company's general meeting.
DISCLOSURE REGULATION
This information is required to be disclosed under Section 5-12 of the Securities Trading Act.
CONTACTS
Brede Ellingsæter, CFO & COO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
